Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective

[1]  S. Spiegl-Kreinecker,et al.  O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients. , 2010, Neuro-oncology.

[2]  K. Aldape,et al.  A multigene predictor of outcome in glioblastoma. , 2010, Neuro-oncology.

[3]  G. Reifenberger,et al.  NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  R. Mirimanoff,et al.  Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. , 2009, Neuro-oncology.

[5]  Andrew P. Stubbs,et al.  Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. , 2009, Cancer research.

[6]  L. Deangelis,et al.  Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Büchler,et al.  Examination of External Validity in Randomized Controlled Trials for Adjuvant Treatment of Pancreatic Adenocarcinoma , 2009, Pancreas.

[8]  K. Aldape,et al.  Anaplastic Oligodendroglial Tumors: Refining the Correlation among Histopathology, 1p 19q Deletion and Clinical Outcome in Intergroup Radiation Therapy Oncology Group Trial 9402 , 2008, Brain pathology.

[9]  D. Áfra,et al.  Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882). , 2008, European journal of cancer.

[10]  N. Hashimoto,et al.  Gene Expression-Based Molecular Diagnostic System for Malignant Gliomas Is Superior to Histological Diagnosis , 2007, Clinical Cancer Research.

[11]  C. Miller,et al.  Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. J. van den Bent,et al.  1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. , 2006, European journal of cancer.

[13]  Caterina Giannini,et al.  The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors , 2005, Cancer.

[14]  P. Rothwell,et al.  External validity of randomised controlled trials: “To whom do the results of this trial apply?” , 2005, The Lancet.

[15]  A. Algra,et al.  Oligoastrocytomas: a clinicopathological study of 52 cases , 1997, Journal of Neuro-Oncology.

[16]  T. Golub,et al.  Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. , 2003, Cancer research.

[17]  M. J. van den Bent,et al.  Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features , 2003, Cancer.

[18]  P. Burger,et al.  What is an Oligodendroglioma? , 2002, Brain pathology.

[19]  Rebecca A Betensky,et al.  Histopathological‐Molecular Genetic Correlations in Referral Pathologist‐Diagnosed Low‐Grade “Oligodendroglioma” , 2002, Journal of neuropathology and experimental neurology.

[20]  B. Scheithauer,et al.  Oligodendrogliomas: Reproducibility and Prognostic Value of Histologic Diagnosis and Grading , 2001, Journal of neuropathology and experimental neurology.

[21]  M. Brada.  Pathology and Genetics of Tumours of the Nervous System , 2001, British Journal of Cancer.

[22]  G. Barger,et al.  Discrepancies in diagnoses of neuroepithelial neoplasms , 2000, Cancer.

[23]  B. Scheithauer,et al.  Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  D. Louis,et al.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.

[25]  A. Twijnstra,et al.  Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy , 1998, Neurology.

[26]  D. Louis,et al.  Molecular Genetic Evidence for Subtypes of Oligoastrocytomas , 1997, Journal of neuropathology and experimental neurology.

[27]  D K Pearl,et al.  Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas , 1997, Cancer.

[28]  G. Fuller,et al.  Diagnostic discrepancies and their clinical impact in a neuropathology referral practice , 1997, Cancer.

[29]  D. Nelson,et al.  Central pathology review in clinical trials for patients with malignant glioma. A report of radiation therapy oncology group 83‐02 , 1995, Cancer.

[30]  A R Feinstein,et al.  The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. , 1985, The New England journal of medicine.